Abstract 1092: Defining the molecular phenotypes of metastatic castration-resistant prostate cancer sensitive to FGF pathway inhibition

Castration Resistant ◽

Pathway Inhibition ◽

Molecular Phenotypes

Abstract 5691: SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt pathway inhibition in castration-resistant prostate cancer (CRPC) models

10.1158/1538-7445.am2020-5691 ◽

2020 ◽

Author(s):

Carine Bossard ◽

Nathalia Cruz ◽

Kevin Chiu ◽

Brian Eastman ◽

Chi Ching Mak ◽

...

Keyword(s):

Prostate Cancer ◽

Small Molecule ◽

Wnt Pathway ◽

Antitumor Effects ◽

Castration Resistant ◽

Pathway Inhibition

Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-21-1625 ◽

2021 ◽

pp. clincanres.CCR-21-1625-E.2021

Author(s):

Matti Annala ◽

Sinja Taavitsainen ◽

Daniel J Khalaf ◽

Gillian Vandekerkhove ◽

Kevin Beja ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Castration Resistant ◽

Pathway Inhibition

Targeting reciprocal feedback inhibition in the clinic: ARN509 and PI3K pathway inhibition in patients with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps5106 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS5106-TPS5106

Author(s):

Dana E. Rathkopf ◽

Brett Stewart Carver ◽

Yu Chen ◽

Michael J. Morris ◽

Daniel Costin Danila ◽

...

Keyword(s):

Prostate Cancer ◽

Feedback Inhibition ◽

Pi3k Pathway ◽

Castration Resistant ◽

Pathway Inhibition

Neuroendocrine secretory profiles are not associated with treatment response to Lu-177-PSMA-617 radioligand therapy in patients with advanced metastatic castration-resistant prostate cancer

10.1055/s-0040-1708342 ◽

2020 ◽

Author(s):

T Derlin ◽

R Werner ◽

C Henkenberens ◽

TL Ross ◽

FM Bengel

Keyword(s):

Prostate Cancer ◽

Treatment Response ◽

Radioligand Therapy ◽

Prostate specific membrane antigen targeted radioligand therapy of metastatic castration-resistant prostate cancer using Lu-177 PSMA-617: safety, efficacy and dosimetry in comparison with Lu-177 PSMA I&T

Endocrine Abstracts ◽

10.1530/endoabs.47.oc32 ◽

2016 ◽

Author(s):

Harshad R. Kulkarni ◽

Aviral Singh ◽

Christiane Schuchardt ◽

Karin Niepsch ◽

Richard P. Baum

Keyword(s):

Prostate Cancer ◽

Prostate Specific Membrane Antigen ◽

Radioligand Therapy ◽

Castration Resistant ◽

Specific Membrane

New combination therapies for castration-resistant prostate cancer

Oncology Abstracts ◽

10.1530/oncolabs.1.p031 ◽

2019 ◽

Author(s):

Mitchell G Lawrence ◽

Laura H Porter ◽

Daisuke Obinata ◽

Shahneen Sandhu ◽

Luke A Selth ◽

...

Keyword(s):

Prostate Cancer ◽

New Combination ◽

Combination Therapies ◽

The role of microbiota in driving castration-resistant prostate cancer

10.26226/morressier.5f69edb69b74b699bf38c5cf ◽

2020 ◽

Author(s):

Arianna Calcinotto

Keyword(s):

Prostate Cancer ◽

FDA approves darolutamide for non-metastatic castration-resistant prostate cancer

Case Medical Research ◽

10.31525/cmr-1904aca ◽

2019 ◽

Author(s):

Keyword(s):

Prostate Cancer ◽

A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Case Medical Research ◽

10.31525/ct1-nct03851640 ◽

2019 ◽

Author(s):

Keyword(s):

Prostate Cancer ◽

Efficacy And Safety ◽

177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer

Case Medical Research ◽

10.31525/ct1-nct03874884 ◽

2019 ◽

Author(s):

Keyword(s):

Prostate Cancer ◽